MXCT Company Profile and Key Details

MXCT has shown weak momentum, losing -11.03% over the past week and -24.84% over the past quarter, though year-to-date performance is down -21.94%. Short-term trend indicators are bullishly aligned (SMA20 0.42%, SMA50 -31.56%, SMA200 -51.78%). The stock’s 14-day RSI is 35.05 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.52% below its high and over 23.19% above its low. Average 10-day trading volume of 494.88 thousand shares is below the 3-month average of 958.52 thousand, indicating normal recent market interest.

MaxCyte, Inc. generated EPS of -$0.43 over the past year. Five-year average earnings growth is -11.37%. Wall Street analysts project EPS growth of 14.43% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$6.12. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $5.00. The high target offers 605.88% upside. The low target suggests 488.24% downside. The mean target is $5.50. This offers 547.06% upside. MaxCyte, Inc. earnings surprise history is a mixed track record. The quarter that ended March 24, 2026, missed forecasts by -25.0%. The prior quarter beat by 18.91%. Over the last six quarters, Apple has recorded several small beats. These include -15.38% in November 06, 2024.

MaxCyte, Inc. has 106.67 million shares outstanding. The public float is 105.17 million shares, elevated short interest at 4.80% of float. This equals 5.09 million shares. The short ratio is 3.69 days. Institutional investors hold 66.74% of the float. Insiders own 1.4%. Casdin Partners Master Fund, L.P. holds 10.00 million shares, Casdin Eli has 10.00 million shares and Erck Stanley C has 398.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.14 thousand shares across 1 transactions.

MaxCyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.64 and $2.74. With a market capitalization of about $90.48 million, MaxCyte, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.45). Key stats such as the average daily volume over the past year has been around 969.43 thousand shares, volume is running light vs its 52-week average. Headquartered in Rockville, MD, MaxCyte, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Maher Masoud, the company employs approximately 114 people and listed since July 30, 2021. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.

MaxCyte, Inc. trades at a P/E ratio of -2.01, slightly below the S&P 500 average, with a price-to-sales ratio of 2.73 and a price-to-book ratio of 0.52 suggesting the stock is closer to book value. The P/FCF stands at -2.49, also below market averages.

MaxCyte, Inc. (NASDAQ:MXCT) shares are down -21.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MaxCyte, Inc. trading at a premium to the broader market with a P/E of -2.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.50, suggesting 903.9% upside. Our AI forecast model points to short-term strength (7.48% over two weeks), a medium-term fall (-23.23% over three months), and a longer-term loss (-35.04% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MaxCyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.48%, with price expected at $0.91 by May 20, 2026, within a range of $0.86 to $0.95 3-Month Outlook: Projected fall of -23.23%, reaching $0.65 by August 04, 2026, with a range of $0.46 to $0.71. 1-Year Outlook: Projected loss of -35.04%, with price at $0.55 by May 06, 2027, within a range of $0.30 to $0.63.